Showing 1921-1930 of 5696 results for "".
- Retina Consultants of America Expands Washington State Footprint Through Partnership with Retina Center Northwesthttps://modernod.com/news/retina-consultants-of-america-expands-washington-state-footprint-through-partnership-with-retina-center-northwest/2480726/Retina Consultants of America (RCA), a physician management services organization, has added Retina Center Northwest (RCNW) in Washington state,. Terms of the deal were not disclosed. With the addition of RCNW, RCA adds to its presence in the Pacific Northwest, and
- NovaSight Announces Successful Results of Pivotal Amblyopia Treatment Trialhttps://modernod.com/news/novasight-announces-successful-results-of-pivotal-amblyopia-treatment-trial/2480689/NovaSight announced positive pivotal data from its multicenter, randomized, controlled trial of CureSight, an eye-tracking based, digital treatment device for amblyopia (lazy eye). The study, which randomized 103 participants aged 4 to 9, compared the improvement in visual outcomes achieved
- Novartis Presents Positive Results From Three Phase 3 Trials of Beovu in DMEhttps://modernod.com/news/novartis-presented-positive-results-from-three-phase-3-trials-of-beovu-in-dme/2480638/At the Angiogenesis, Exudation, and Degeneration 2022 Virtual Meeting, Novartis presented additional positive results from three phase 3 trials of Beovu in DME, including results from patients dosed at up to 16-week intervals. This was the first detailed presentation of the year 2 results&nb
- Novartis Acquires Gyroscope Therapeutics, Maker of Investigational Gene Therapy for Geographic Atrophyhttps://modernod.com/news/novartis-acquires-gyroscope-therapeutics-maker-of-investigational-gene-therapy-for-geographic-atrophy/2480532/Novartis has bolstered it gene therapy portfolio after entering into a definitive agreement to acquire all of the outstanding share capital of the UK-based ocular gene therapy company Gyroscope Therapeutics. Novartis will make an upfront payment of $800 million and potential additi
- GenSight Biologics Announces Publication of Non-Human Primate Study Reporting Presence of Lumevoq Vector DNA in Contralateral Eyes After Unilateral Injectionhttps://modernod.com/news/gensight-biologics-announces-publication-of-non-human-primate-study-reporting-presence-of-lumevoq-vector-dna-in-contralateral-eyes-after-unilateral-injection/2480491/GenSight Biologics announced that the journal "Molecular Therapy – Methods and Clinical Development" has published the results of a mechanistic study demonstrating the transfer of Lumevoq vector DNA from the injected eyes to the non-injected eyes of non-human prim
- LayerBio Granted U.S. Patent for OcuRing Drug Delivery Platformhttps://modernod.com/news/layerbio-granted-us-patent-for-ocuring-drug-delivery-platform/2480486/LayerBio announced that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 11,185,441. "This patent issuance marks an important milestone for the OcuRing platform and recognition of novelty and uniqueness of our drug delivery technology,&
- Notal Vision Monitoring Center Reports AI Analysis of 10 Million ForeseeHome AMD Home Monitoring Testshttps://modernod.com/news/notal-vision-monitoring-center-reports-ai-analysis-of-10-million-foreseehome-amd-home-monitoring-tests/2480482/The Notal Vision Monitoring Center celebrates the artificial intelligence (AI) based analysis of the ten millionth test performed by over 20,000 patients with the FDA-cleared ForeseeHome devic
- IACTA Pharmaceuticals Receives U.S. Department of Defense Funding of $1 Million to Conduct Preclinical Studies of IC 800 to Treat Pain Relief for Eye Injuryhttps://modernod.com/news/iacta-pharmaceuticals-receives-us-department-of-defense-funding-of-1-million-to-conduct-preclinical-studies-of-ic-800-to-treat-pain-relief-for-eye-injury/2480382/IACTA Pharmaceuticals announced that the U.S. Army Medical Research Acquisition Activity (USAMRAA), a division of the Department of Defense, has granted a $1 million award to the company to fund preclinical studies of IC 800, a novel therapy for the topical treatment of ocular pain utilizing
- Outlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trialhttps://modernod.com/news/outlook-therapeutics-reports-new-positive-12-month-safety-data-from-pivotal-phase-3-norse-two-trial/2480308/Outlook Therapeutics announced new 12-month safety data from the pivotal phase 3 NORSE TWO trial that further confirm the strong safety profile in this study of ONS-5010/Lytenava (bevacizumab-vikg) for treatment of wet age-related macular degeneration (AMD). In August 2021, Outlook Ther
- Nicox’s NCX 470 Shows Retinal Cell Protection in a Nonclinical Modelhttps://modernod.com/news/nicoxs-ncx-470-shows-retinal-cell-protection-in-a-nonclinical-model/2480307/Nicox reported new data on NCX 470 in a nonclinical model of retinal cell damage induced by endothelin-1 (ET-1). NCX 470, Nicox’s lead clinical candidate, is a nitric oxide-donating prostaglandin analog currently in phase 3 clinical development for lowering IOP in patients with op